The translation of new discoveries in medicine to clinical routine has never been easy.
During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible.
However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases.
Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage.
This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
Abstracting & Indexing
ScopusGoogle ScholarDirectory of Open Access Journals (DOAJ)Web of Science
Detailed Metrics
Total Docs. (latest)
1,114
Total Docs. (3 years)
5,543
Total Refs.
69,377
Total Citations (3 years)
32,751
Citable Docs. (3 years)
5,192
Citations / Doc. (2 years)
5.52
Ref. / Doc.
62.28
% Female
39.2%
Metrics Visualization
Latest year data vs 3-year cumulative figures
Female: 39.2% |
Male: 60.8%
Citations / Doc. (2yr)5.52
High impact
References / Doc.62.28
High refs
Citable / Total Docs (3yr)93.7%
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Frequently Asked Questions
What is the impact factor of Frontiers in Bioengineering and Biotechnology?
The official Journal Impact Factor (JIF) is published by Clarivate in the Journal Citation Reports (JCR) and is not listed on this page. Based on SCImago data, Frontiers in Bioengineering and Biotechnology has an SJR of 1.024 and is ranked Q1.
What is the SJR and quartile of Frontiers in Bioengineering and Biotechnology?
Frontiers in Bioengineering and Biotechnology has an SJR (SCImago Journal Rank) of 1.024 and its best quartile is Q1.
What is the H-index of Frontiers in Bioengineering and Biotechnology?
The H-index of Frontiers in Bioengineering and Biotechnology is 144, meaning 144 of its articles have each been cited at least 144 times.
Is Frontiers in Bioengineering and Biotechnology indexed in Scopus?
Yes. Frontiers in Bioengineering and Biotechnology is active in Scopus (Scopus Source List, August 2026).